IBDEI1L0 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28073,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,28073,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,28073,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,28074,0)
 ;;=201.90^^162^1791^81
 ;;^UTILITY(U,$J,358.3,28074,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28074,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,28074,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,28074,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,28075,0)
 ;;=785.6^^162^1791^87
 ;;^UTILITY(U,$J,358.3,28075,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28075,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,28075,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,28075,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,28076,0)
 ;;=200.20^^162^1791^90
 ;;^UTILITY(U,$J,358.3,28076,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28076,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,28076,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,28076,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,28077,0)
 ;;=202.00^^162^1791^89
 ;;^UTILITY(U,$J,358.3,28077,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28077,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,28077,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Site Unspec
 ;;^UTILITY(U,$J,358.3,28077,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,28078,0)
 ;;=200.10^^162^1791^88
 ;;^UTILITY(U,$J,358.3,28078,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28078,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,28078,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Site Unspec
 ;;^UTILITY(U,$J,358.3,28078,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,28079,0)
 ;;=273.3^^162^1791^91
 ;;^UTILITY(U,$J,358.3,28079,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28079,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,28079,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,28079,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,28080,0)
 ;;=203.00^^162^1791^104
 ;;^UTILITY(U,$J,358.3,28080,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28080,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,28080,1,5,0)
 ;;=5^Multiple Myeloma w/o Rem
 ;;^UTILITY(U,$J,358.3,28080,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,28081,0)
 ;;=203.01^^162^1791^103
 ;;^UTILITY(U,$J,358.3,28081,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28081,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,28081,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,28081,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,28082,0)
 ;;=238.6^^162^1791^106
 ;;^UTILITY(U,$J,358.3,28082,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28082,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,28082,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,28082,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,28083,0)
 ;;=205.00^^162^1791^4
 ;;^UTILITY(U,$J,358.3,28083,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28083,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,28083,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,28083,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,28084,0)
 ;;=205.01^^162^1791^6
 ;;^UTILITY(U,$J,358.3,28084,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28084,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,28084,1,5,0)
 ;;=5^AML, In Remission
 ;;^UTILITY(U,$J,358.3,28084,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,28085,0)
 ;;=205.10^^162^1791^49
 ;;^UTILITY(U,$J,358.3,28085,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28085,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,28085,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,28085,2)
 ;;=^267533
 ;;^UTILITY(U,$J,358.3,28086,0)
 ;;=205.11^^162^1791^51
 ;;^UTILITY(U,$J,358.3,28086,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,28086,1,4,0)
 ;;=4^205.11
 ;;^UTILITY(U,$J,358.3,28086,1,5,0)
 ;;=5^CML, In Remission
 ;;
 ;;$END ROU IBDEI1L0
